Propranolol and infantile hemangiomas four years later: A systematic review

Ann L. Marqueling, Vikash Oza, Ilona J. Frieden, Katherine Brown Puttgen

Research output: Contribution to journalArticle

Abstract

To systematically review the literature evaluating efficacy and adverse events of propranolol treatment for infantile hemangiomas, we searched the MEDLINE and Cochrane databases for all studies examining the response of infantile hemangiomas (IHs) to propranolol published between June 12, 2008, and June 15, 2012. Forty-one studies with 1,264 patients were included; 74% of patients were female and approximately 30% had received other treatments before propranolol. Propranolol was initiated at a mean age of 6.6 months at a mean dose of 2.1 mg/kg/day and for a mean treatment duration of 6.4 months. The response rate for patients with IHs treated with propranolol was 98% (range 82%-100%), with response rate defined as any improvement with propranolol. Treatment response rates were comparable for studies evaluating IHs at specific sites, such as periorbital IHs. Studies that followed patients after treatment completion reported IH rebound growth in 17% of patients. There were 371 adverse events reported in 1,189 patients. The most common adverse events were changes in sleep (n = 136) and acrocyanosis (n = 61). Serious adverse events were rare, with reports of symptomatic hypotension in five patients, hypoglycemia in four, and symptomatic bradycardia in one. This systematic review of 1,264 patients treated with propranolol for IHs showed a high rate of efficacy and a low rate of serious adverse events.

Original languageEnglish (US)
Pages (from-to)182-191
Number of pages10
JournalPediatric Dermatology
Volume30
Issue number2
DOIs
StatePublished - Mar 2013

Fingerprint

Hemangioma
Propranolol
Therapeutics
Bradycardia
Hypoglycemia
MEDLINE
Hypotension
Sleep
Databases
Growth

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Cite this

Marqueling, A. L., Oza, V., Frieden, I. J., & Puttgen, K. B. (2013). Propranolol and infantile hemangiomas four years later: A systematic review. Pediatric Dermatology, 30(2), 182-191. https://doi.org/10.1111/pde.12089

Propranolol and infantile hemangiomas four years later : A systematic review. / Marqueling, Ann L.; Oza, Vikash; Frieden, Ilona J.; Puttgen, Katherine Brown.

In: Pediatric Dermatology, Vol. 30, No. 2, 03.2013, p. 182-191.

Research output: Contribution to journalArticle

Marqueling, AL, Oza, V, Frieden, IJ & Puttgen, KB 2013, 'Propranolol and infantile hemangiomas four years later: A systematic review', Pediatric Dermatology, vol. 30, no. 2, pp. 182-191. https://doi.org/10.1111/pde.12089
Marqueling, Ann L. ; Oza, Vikash ; Frieden, Ilona J. ; Puttgen, Katherine Brown. / Propranolol and infantile hemangiomas four years later : A systematic review. In: Pediatric Dermatology. 2013 ; Vol. 30, No. 2. pp. 182-191.
@article{db2131d846a444538bb666dac7a3183a,
title = "Propranolol and infantile hemangiomas four years later: A systematic review",
abstract = "To systematically review the literature evaluating efficacy and adverse events of propranolol treatment for infantile hemangiomas, we searched the MEDLINE and Cochrane databases for all studies examining the response of infantile hemangiomas (IHs) to propranolol published between June 12, 2008, and June 15, 2012. Forty-one studies with 1,264 patients were included; 74{\%} of patients were female and approximately 30{\%} had received other treatments before propranolol. Propranolol was initiated at a mean age of 6.6 months at a mean dose of 2.1 mg/kg/day and for a mean treatment duration of 6.4 months. The response rate for patients with IHs treated with propranolol was 98{\%} (range 82{\%}-100{\%}), with response rate defined as any improvement with propranolol. Treatment response rates were comparable for studies evaluating IHs at specific sites, such as periorbital IHs. Studies that followed patients after treatment completion reported IH rebound growth in 17{\%} of patients. There were 371 adverse events reported in 1,189 patients. The most common adverse events were changes in sleep (n = 136) and acrocyanosis (n = 61). Serious adverse events were rare, with reports of symptomatic hypotension in five patients, hypoglycemia in four, and symptomatic bradycardia in one. This systematic review of 1,264 patients treated with propranolol for IHs showed a high rate of efficacy and a low rate of serious adverse events.",
author = "Marqueling, {Ann L.} and Vikash Oza and Frieden, {Ilona J.} and Puttgen, {Katherine Brown}",
year = "2013",
month = "3",
doi = "10.1111/pde.12089",
language = "English (US)",
volume = "30",
pages = "182--191",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Propranolol and infantile hemangiomas four years later

T2 - A systematic review

AU - Marqueling, Ann L.

AU - Oza, Vikash

AU - Frieden, Ilona J.

AU - Puttgen, Katherine Brown

PY - 2013/3

Y1 - 2013/3

N2 - To systematically review the literature evaluating efficacy and adverse events of propranolol treatment for infantile hemangiomas, we searched the MEDLINE and Cochrane databases for all studies examining the response of infantile hemangiomas (IHs) to propranolol published between June 12, 2008, and June 15, 2012. Forty-one studies with 1,264 patients were included; 74% of patients were female and approximately 30% had received other treatments before propranolol. Propranolol was initiated at a mean age of 6.6 months at a mean dose of 2.1 mg/kg/day and for a mean treatment duration of 6.4 months. The response rate for patients with IHs treated with propranolol was 98% (range 82%-100%), with response rate defined as any improvement with propranolol. Treatment response rates were comparable for studies evaluating IHs at specific sites, such as periorbital IHs. Studies that followed patients after treatment completion reported IH rebound growth in 17% of patients. There were 371 adverse events reported in 1,189 patients. The most common adverse events were changes in sleep (n = 136) and acrocyanosis (n = 61). Serious adverse events were rare, with reports of symptomatic hypotension in five patients, hypoglycemia in four, and symptomatic bradycardia in one. This systematic review of 1,264 patients treated with propranolol for IHs showed a high rate of efficacy and a low rate of serious adverse events.

AB - To systematically review the literature evaluating efficacy and adverse events of propranolol treatment for infantile hemangiomas, we searched the MEDLINE and Cochrane databases for all studies examining the response of infantile hemangiomas (IHs) to propranolol published between June 12, 2008, and June 15, 2012. Forty-one studies with 1,264 patients were included; 74% of patients were female and approximately 30% had received other treatments before propranolol. Propranolol was initiated at a mean age of 6.6 months at a mean dose of 2.1 mg/kg/day and for a mean treatment duration of 6.4 months. The response rate for patients with IHs treated with propranolol was 98% (range 82%-100%), with response rate defined as any improvement with propranolol. Treatment response rates were comparable for studies evaluating IHs at specific sites, such as periorbital IHs. Studies that followed patients after treatment completion reported IH rebound growth in 17% of patients. There were 371 adverse events reported in 1,189 patients. The most common adverse events were changes in sleep (n = 136) and acrocyanosis (n = 61). Serious adverse events were rare, with reports of symptomatic hypotension in five patients, hypoglycemia in four, and symptomatic bradycardia in one. This systematic review of 1,264 patients treated with propranolol for IHs showed a high rate of efficacy and a low rate of serious adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84874944656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874944656&partnerID=8YFLogxK

U2 - 10.1111/pde.12089

DO - 10.1111/pde.12089

M3 - Article

C2 - 23405852

AN - SCOPUS:84874944656

VL - 30

SP - 182

EP - 191

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 2

ER -